{"id":"https://openalex.org/W2809832311","doi":"https://doi.org/10.1158/1538-7445.am2018-lb-128","title":"Abstract LB-128: The aryl hydrocarbon receptor as driver of cancer immunity","display_name":"Abstract LB-128: The aryl hydrocarbon receptor as driver of cancer immunity","publication_year":2018,"publication_date":"2018-07-01","ids":{"openalex":"https://openalex.org/W2809832311","doi":"https://doi.org/10.1158/1538-7445.am2018-lb-128","mag":"2809832311"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2018-lb-128","doi":"https://doi.org/10.1158/1538-7445.am2018-lb-128","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-lb-128","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067639617","display_name":"David H. Sherr","orcid":"https://orcid.org/0000-0003-3353-0553","observed_orcids":["https://orcid.org/0000-0003-3353-0553"]},"institutions":[{"id":"https://openalex.org/I111088046","display_name":"Boston University","ror":"https://ror.org/05qwgg493","country_code":"US","type":"education","lineage":["https://openalex.org/I111088046"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Sherr","raw_affiliation_strings":["Boston University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston University, Boston, MA","institution_ids":["https://openalex.org/I111088046"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026009339","display_name":"Jessica E. Kenison","orcid":"https://orcid.org/0000-0002-5599-3228","observed_orcids":["https://orcid.org/0000-0002-5599-3228"]},"institutions":[{"id":"https://openalex.org/I111088046","display_name":"Boston University","ror":"https://ror.org/05qwgg493","country_code":"US","type":"education","lineage":["https://openalex.org/I111088046"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Kenison-Whte","raw_affiliation_strings":["Boston University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston University, Boston, MA","institution_ids":["https://openalex.org/I111088046"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101828863","display_name":"Zhongyan Wang","orcid":"https://orcid.org/0000-0003-4484-1269","observed_orcids":["https://orcid.org/0000-0003-4484-1269"]},"institutions":[{"id":"https://openalex.org/I111088046","display_name":"Boston University","ror":"https://ror.org/05qwgg493","country_code":"US","type":"education","lineage":["https://openalex.org/I111088046"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhongyan Wang","raw_affiliation_strings":["Boston University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston University, Boston, MA","institution_ids":["https://openalex.org/I111088046"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I111088046"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"78","issue":"13_Supplement","first_page":"LB","last_page":"128"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.3801000118255615,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.3801000118255615,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.26930001378059387,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11313","display_name":"Immune cells in cancer","score":0.15970000624656677,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aryl-hydrocarbon-receptor","display_name":"aryl hydrocarbon receptor","score":1.0},{"id":"https://openalex.org/keywords/tumor-immunosuppression","display_name":"tumor immunosuppression","score":0.8399999737739563},{"id":"https://openalex.org/keywords/tryptophan-metabolism","display_name":"tryptophan metabolism","score":0.7900000214576721},{"id":"https://openalex.org/keywords/kynurenine-pathway","display_name":"kynurenine pathway","score":0.9169999957084656},{"id":"https://openalex.org/keywords/tumor-associated-myeloid-cells","display_name":"tumor-associated myeloid cells","score":0.7770000100135803},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.7599999904632568},{"id":"https://openalex.org/keywords/ccr2","display_name":"CCR2","score":0.8149999976158142},{"id":"https://openalex.org/keywords/tumor-infiltrating-t-cells","display_name":"tumor-infiltrating T cells","score":0.8859999775886536},{"id":"https://openalex.org/keywords/oral-cancer","display_name":"oral cancer","score":0.8809999823570251},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9929999709129333},{"id":"https://openalex.org/keywords/skin-cancer","display_name":"skin cancer","score":0.8080000281333923},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.6370000243186951},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.4339999854564667}],"concepts":[{"id":"https://openalex.org/C33594762","wikidata":"https://www.wikidata.org/wiki/Q155750","display_name":"Aryl hydrocarbon receptor","level":4,"score":0.8851944208145142},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6459951400756836},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6100438237190247},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.5223061442375183},{"id":"https://openalex.org/C2779341262","wikidata":"https://www.wikidata.org/wiki/Q182581","display_name":"Immunity","level":3,"score":0.5036153197288513},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4919862449169159},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4799416661262512},{"id":"https://openalex.org/C2779727006","wikidata":"https://www.wikidata.org/wiki/Q426188","display_name":"FOXP3","level":3,"score":0.46300509572029114},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.4536721706390381},{"id":"https://openalex.org/C2780252810","wikidata":"https://www.wikidata.org/wiki/Q1455316","display_name":"Immunosuppression","level":2,"score":0.4427160322666168},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.43921029567718506},{"id":"https://openalex.org/C2779256057","wikidata":"https://www.wikidata.org/wiki/Q16909647","display_name":"Tumor progression","level":3,"score":0.4279709756374359},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.34204035997390747},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.13919901847839355},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.08273017406463623},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2018-lb-128","doi":"https://doi.org/10.1158/1538-7445.am2018-lb-128","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-lb-128","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9907000064849854,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4282930398","https://openalex.org/W4313408027","https://openalex.org/W7097110213","https://openalex.org/W2010169874","https://openalex.org/W2955495535","https://openalex.org/W2794174776","https://openalex.org/W3151647854","https://openalex.org/W4210689626","https://openalex.org/W4388079234","https://openalex.org/W4385685324"],"abstract_inverted_index":{"Abstract":[0],"The":[1,94,276],"Aryl":[2],"Hydrocarbon":[3],"Receptor":[4],"(AHR)":[5],"has":[6],"been":[7],"identified":[8],"as":[9,280],"a":[10,64,99,180,198,262],"driver":[11,65,281],"of":[12,46,66,113,134,155,183,218,239,254,282,288],"cancer":[13,16,67,86,266,283],"progression":[14],"and":[15,53,76,88,118,160,165,257],"immunity":[17,284],"in":[18,41,83,110,122,139,147,171,221],"the":[19,23,61,126,132,140,153,209,216,219,222,247,289],"tryptophan-IDO/TDO-kynurenine-AHR":[20],"pathway.":[21],"Over":[22],"last":[24],"10":[25],"years,":[26],"studies":[27],"from":[28],"several":[29,206,255],"laboratories":[30],"have":[31],"demonstrated":[32],"that":[33,60,98,215,233,246,258],"AHR":[34,44,62,81,102,145,220,248],"ligand-mediated":[35],"immunosuppression":[36],"is":[37,63,177,225],"effected,":[38],"at":[39],"least":[40],"part,":[42],"through":[43],"regulation":[45],"inflammatory":[47],"or":[48,136],"inhibitory":[49],"T":[50,167],"cell":[51],"subsets":[52],"immune":[54,92],"suppressive":[55],"MDSCs.":[56],"These":[57,212,242],"results":[58,243],"suggest":[59,214,232,245],"immunity.":[68,241],"To":[69],"test":[70],"this":[71],"hypothesis,":[72],"we":[73],"used":[74],"molecular":[75],"pharmacological":[77],"approaches":[78],"to":[79,197,227,265],"regulate":[80],"activity":[82],"multiple":[84,91],"murine":[85],"models":[87,112],"then":[89],"measured":[90],"phenotypes.":[93],"resulting":[95],"data":[96,213,231],"indicate":[97],"novel,":[100],"non-toxic":[101],"inhibitor,":[103],"HP163":[104,129,259],"(Hercules":[105],"Pharmaceuticals),":[106],"reduces":[107,131],"tumor":[108,141,157,162,185,223,240],"growth":[109],"orthotopic":[111,184],"oral":[114],"(MOC1),":[115],"breast":[116],"(4T1),":[117],"skin":[119],"(B16)":[120],"cancers":[121,256],"immunocompetent":[123],"hosts.":[124],"In":[125],"MOC1":[127,148,204],"model,":[128],"significantly":[130],"number":[133],"CD11b+PD-L1+":[135,156],"CD11b+CCR2+":[137],"cells":[138,149,159,172,194,205,236],"draining":[142],"lymph":[143],"node.":[144],"knockdown":[146],"with":[150,173,201],"CRISPR/Cas9":[151],"decreases":[152],"percentage":[154],"infiltrating":[158,163],"increases":[161],"CD4+":[164],"CD8+":[166],"cells.":[168],"This":[169],"decrease":[170],"an":[174],"immunosuppressive":[175],"phenotype":[176],"accompanied":[178],"by":[179],"complete":[181],"lack":[182],"growth.":[186],"Furthermore,":[187],"mice":[188],"having":[189],"received":[190],"AHR-":[191],"MOC":[192],"1":[193],"are":[195],"resistant":[196],"second":[199],"challenge":[200],"wildtype":[202],"AHR+":[203,234],"months":[207],"after":[208],"primary":[210],"inoculation.":[211],"presence":[217],"itself":[224],"sufficient":[226],"induce":[228],"immunosuppression.":[229],"Preliminary":[230],"myeloid":[235],"mediate":[237],"suppression":[238],"collectively":[244],"may":[249,260],"be":[250],"targeted":[251],"for":[252,292],"immunotherapy":[253],"represent":[261],"novel":[263],"approach":[264],"therapy.":[267],"Citation":[268],"Format:":[269],"David":[270],"Sherr,":[271],"Jessica":[272],"Kenison-Whte,":[273],"Zhongyan":[274],"Wang.":[275],"aryl":[277],"hydrocarbon":[278],"receptor":[279],"[abstract].":[285],"In:":[286],"Proceedings":[287],"American":[290],"Association":[291],"Cancer":[293,306],"Research":[294],"Annual":[295],"Meeting":[296],"2018;":[297],"2018":[298],"Apr":[299],"14-18;":[300],"Chicago,":[301],"IL.":[302],"Philadelphia":[303],"(PA):":[304],"AACR;":[305],"Res":[307],"2018;78(13":[308],"Suppl):Abstract":[309],"nr":[310],"LB-128.":[311]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2018-07-10T00:00:00"}